A
Apimeds Pharmaceuticals US Inc
AMEX:APUS
Apimeds Pharmaceuticals US Inc
AMEX:APUS
Price:
5.2
USD
3.59%
Market Closed
Market Cap:
$7.9m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
A
|
Apimeds Pharmaceuticals US Inc
AMEX:APUS
|
US |
|
Enseval Putera Megatrading Tbk PT
IDX:EPMT
|
ID |
|
T
|
Thai Mitsuwa PCL
SET:TMW
|
TH |
|
Philogen SpA
MIL:PHIL
|
IT |
|
B
|
Bluebik Group PCL
SET:BBIK
|
TH |
|
P
|
Prabos Plus as
PSE:PRAB
|
CZ |
|
U
|
Ubon Bio Ethanol PCL
SET:UBE
|
TH |
|
U
|
Union Plastic PCL
SET:UP
|
TH |
|
Molecular Partners AG
SIX:MOLN
|
CH |
|
STRABAG SE
VSE:STR
|
AT |
Intrinsic Value
Not Available for APUS
There is not enough data to reliably calculate the intrinsic value for Apimeds Pharmaceuticals US Inc.
Do our valuations actually work? See backtest results .
Alternatives to APUS
Fundamental Analysis
What Apimeds Pharmaceuticals US Does
Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that engages in the development of Apitox, an intradermally administered bee venom-based toxin. The company is headquartered in Matawan, New Jersey and currently employs 2 full-time employees. The company went IPO on 2025-05-09. The firm is engaged in developing Apitox, an intradermally administered bee venom-based toxin.
- Headquarters
- United States of America US
- Employees
- 2
- IPO date
- May 9, 2025
Financials
Efficiency
Earnings Waterfall
Apimeds Pharmaceuticals US Inc
Apimeds Pharmaceuticals US Inc
